Travere Therapeutics, Inc.
High uncertainty:The valuation methods show significant disagreement (>100% spread). Treat the range as a rough guide rather than a precise estimate.
Bear Case (25th pct.)
-89.0% vs price
Base Case (Median)
-81.8% vs price
Bull Case (75th pct.)
-76.7% vs price
◇ = Current price | |Bear |Base | Bull
| Method | Est. Value | vs Price | Weight |
|---|---|---|---|
| DCF (Discounted Cash Flow) | $18.06 | -71.6% | High (40%) |
| EV/EBITDA | $2.49 | -96.1% | Medium (20%) |
| EV/FCF | $11.55 | -81.8% | Medium (20%) |
Based on 3 out of 8 methods, TVTX appears overvalued at the current price of $63.53. The base case fair value of $11.55 implies 81.8% downside.
Bear/base/bull cases represent the 25th, 50th, and 75th percentile of available method estimates. This is not financial advice. Valuation is inherently uncertain.